23andMe Health + Ancestry: Consumer Genetics, BRCA Screening, and What Your DNA Actually Tells You

The most recognizable name in consumer genetics offers FDA-authorized health reports alongside ancestry data. But how much clinical value does a saliva test deliver, and where do its limitations begin?

Presented By Our Partners

Somewhere between 1% and 3% of the general population in the United States carries a genetic variant that predisposes them to a clinically actionable hereditary disease, yet most will never know it. A 2022 systematic review published in Frontiers in Genetics by Shen et al. examined barriers and facilitators to population genetic screening and found that inadequate knowledge and perceived limited clinical utility were the primary obstacles preventing both healthcare providers and patients from pursuing genetic testing. The irony is striking: the science of human genetics has advanced to the point where a saliva sample can identify carriers of BRCA1/2 mutations (associated with dramatically elevated breast and ovarian cancer risk), APOE variants linked to Alzheimer’s disease risk, and pharmacogenomic profiles that predict medication response, yet the vast majority of at-risk individuals remain untested. 23andMe, founded in 2006 by Anne Wojcicki, was designed to close this gap by making genetic testing as easy as spitting into a tube and mailing it back. With over 14 million customers genotyped, 23andMe has become the most widely used consumer genetics platform in the world. The question that matters for health, rather than ancestry curiosity, is how much clinical value that saliva test actually delivers.

What Is 23andMe Health + Ancestry?

23andMe Health + Ancestry is a direct-to-consumer (DTC) genetic testing service that analyzes DNA from a saliva sample using a genotyping chip (SNP array) to assess hundreds of thousands of genetic variants across the human genome. The Health + Ancestry kit costs $229 and requires no physician order, prescription, or lab visit. Users provide a saliva sample at home, mail it to 23andMe’s CLIA-certified laboratory, and receive results through a secure online portal within 3 to 5 weeks.

The health component includes FDA-authorized reports on health predispositions (including BRCA1/BRCA2 variants, APOE/Alzheimer’s risk, hereditary thrombophilia, celiac disease, and others), carrier status reports (for conditions like cystic fibrosis, sickle cell anemia, and hereditary hearing loss), pharmacogenomics reports (how genes may affect response to certain medications), and wellness reports (caffeine metabolism, sleep movement, muscle composition). The ancestry component provides ethnicity estimates, DNA relative matching, migration maps, and maternal/paternal haplogroup assignments. 23andMe also offers a raw data download for users who want to upload their genotype information to third-party analysis platforms.

The Science Behind It: What Consumer Genomics Can and Cannot Reveal

The science underlying 23andMe spans two distinct domains: genotyping technology (how the test works) and genomic epidemiology (what the results mean). Understanding both is essential for interpreting 23andMe’s value accurately.

23andMe uses a SNP (single nucleotide polymorphism) genotyping array, not whole genome sequencing. This means the test reads specific genetic positions known to be associated with traits or disease risk, rather than sequencing every base pair in the genome. The current chip covers approximately 730,000 variants. This is a fundamentally different, and less comprehensive, approach than whole genome sequencing (WGS), which reads all 3.2 billion base pairs. The SNP array approach is cost-effective and sufficient for many common variant associations but misses rare variants, structural rearrangements, and novel mutations that WGS can detect.

For the BRCA1/2 health predisposition report, which is 23andMe’s most clinically significant offering, the FDA authorized testing for three specific BRCA variants most common in individuals of Ashkenazi Jewish descent. This is important context: there are over 1,000 known pathogenic BRCA variants, and 23andMe tests for only three. A negative result from 23andMe does not rule out BRCA-related cancer risk, particularly for individuals without Ashkenazi Jewish ancestry. The National Comprehensive Cancer Network (NCCN) guidelines recommend clinical-grade BRCA testing for individuals meeting specific family history criteria, and 23andMe’s test is not a substitute for that clinical assessment.

A 2018 study published in the journal Aging by Levine et al. at UCLA developed the DNAm PhenoAge epigenetic biomarker, demonstrating that biological age markers strongly predict all-cause mortality, cancer, physical functioning, and Alzheimer’s disease across multiple cohorts. While 23andMe does not measure epigenetic age (it measures inherited genetic variants, not acquired methylation patterns), this research illustrates the broader genomics landscape: inherited genetics represent one layer of health risk, while epigenetic modifications represent another. 23andMe captures the genetic layer; epigenetic testing services like TruDiagnostic and Elysium capture the methylation layer. Neither alone provides a complete picture.

A 2021 study published in The Journals of Gerontology by McCrory et al. compared four epigenetic clocks (Horvath, Hannum, PhenoAge, GrimAge) and found that GrimAge significantly outperformed other clocks in predicting clinical phenotypes and all-cause mortality in a cohort of 490 participants followed for up to 10 years. This research underscores that aging biology is increasingly measurable through molecular biomarkers, and the consumer testing landscape is expanding rapidly beyond ancestry-focused genotyping into functional biological age assessment. That is the science. Here is how 23andMe applies it.

What 23andMe Does Well

23andMe’s primary strength is accessibility. No other platform has brought genetic health information to as many consumers with as little friction. The at-home saliva collection eliminates the need for a blood draw, physician order, or lab appointment, which are barriers that the Shen et al. systematic review identified as significant obstacles to genetic screening uptake. At $229, the test is priced within reach of a broad consumer market, and the results are presented through an intuitive online interface designed for non-specialists.

The FDA authorization for specific health reports (including BRCA1/2 variants, pharmacogenomics, and carrier status) provides a regulatory validation that most DTC genetic tests lack. This authorization means that the analytical accuracy of the genotyping for those specific variants has been reviewed and verified by the FDA, a meaningful distinction in a market where many competitors operate under general wellness exemptions.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The 14-million-person database is a significant asset for ancestry analysis and for DNA relative matching, which has proven valuable for adoptees, family reunification, and genealogy research. The sheer scale of the database also contributes to research: 23andMe’s research division has contributed to hundreds of peer-reviewed publications through consented customer data, advancing understanding of the genetic basis of conditions from Parkinson’s disease to depression. For users who value contributing to scientific research while learning about their own genetics, this participatory model is unique.

Pricing, Access, and Practical Realities

The 23andMe Health + Ancestry kit costs $229 as a one-time purchase with no subscription required. Results are accessible indefinitely through the online portal at no additional cost. The company also offers a premium membership ($29 per year) that includes additional health reports, pharmacogenomics updates, and ongoing access to new features as they are released.

No physician order is required. The test is available directly to consumers aged 18 and older (or with parental consent for minors, where available). Results are typically delivered within 3 to 5 weeks of the laboratory receiving the sample. 23andMe is not typically HSA or FSA eligible, as the test is classified as a general wellness product for most plan administrators, though individual plans may vary.

23andMe is not a diagnostic test. The FDA authorization applies to specific health reports for specific variants, and the results are intended to inform, not diagnose. The company explicitly states that results should not be used to make medical decisions without consulting a healthcare provider. Users who receive positive results for BRCA variants or other actionable findings should follow up with a genetic counselor or physician for clinical-grade confirmatory testing.

Who 23andMe Is Best For

23andMe is ideal for health-curious consumers who want a broad overview of their genetic profile, including ancestry composition, carrier status, and selected health predispositions, without the complexity or cost of clinical genetic testing. It serves individuals with Ashkenazi Jewish heritage particularly well, since the FDA-authorized BRCA1/2 screening covers the three variants most prevalent in this population. People interested in pharmacogenomics, who want initial insights into how their genes may affect medication metabolism, will find the reports informative as a starting point for conversations with their prescribing physicians. Genealogy enthusiasts and adoptees seeking family connections benefit from the platform’s massive relative-matching database.

Those who should look elsewhere include individuals with known family histories of hereditary cancer or cardiac disease, who need clinical-grade testing through services like Color Health, Myriad Genetics, or a medical genetics clinic. Anyone seeking comprehensive genomic information should consider whole genome sequencing through Nebula Genomics, which reads every base pair rather than a selected subset. Users primarily interested in biological aging and longevity metrics will not find what they need here; epigenetic age testing from TruDiagnostic, Elysium, or GlycanAge measures the methylation-based biomarkers that predict biological aging and mortality risk.

How 23andMe Compares

AncestryDNA ($99) is the primary competitor for ancestry-focused testing, with an even larger database (over 20 million users) but no FDA-authorized health reports. For users whose interest is purely genealogical, AncestryDNA offers greater relative-matching potential at a lower price. Nebula Genomics ($299 to $999) provides whole genome sequencing at 30x or 100x depth, delivering orders of magnitude more genetic data than 23andMe’s SNP array, along with raw data ownership and a privacy-focused business model. For users who want maximum genomic information, Nebula is more comprehensive but less curated in its health reporting.

Color Health ($249) focuses specifically on hereditary cancer and cardiac disease risk with clinical-grade testing and includes genetic counseling, making it the superior choice for medically actionable screening. GeneSight ($2,000 list price, often insurance-covered) provides clinician-ordered pharmacogenomics testing with deeper clinical validation for psychiatric medication optimization. Among epigenetic testing services, TruDiagnostic ($499) and Elysium Index ($299) measure biological age through DNA methylation, a fundamentally different and complementary dimension of genomic information that 23andMe does not assess.

Limitations and Open Questions

The most significant limitation is the SNP array methodology. By testing only selected genetic positions, 23andMe misses the vast majority of rare and novel pathogenic variants. The BRCA1/2 report tests for 3 of over 1,000 known pathogenic variants, meaning a negative result provides false reassurance for many users, particularly those without Ashkenazi Jewish ancestry. This limitation is disclosed in the results, but consumer understanding of this nuance varies widely.

23andMe has faced significant corporate challenges, including financial losses, a major data breach in 2023 that exposed genetic and personal data for millions of users, and a bankruptcy filing. These events raise legitimate concerns about the long-term security and privacy of genetic data that users have submitted to the platform. Genetic data, unlike a credit card number, cannot be changed if compromised, making the privacy implications of a breach uniquely permanent.

The health reports, while FDA-authorized for specific variants, represent a small fraction of the genetic factors influencing disease risk. Polygenic risk scores, which aggregate the effects of thousands of common variants, are not yet included in standard 23andMe reports, limiting the test’s ability to quantify risk for complex conditions like heart disease, diabetes, or most cancers. The gap between what consumers expect from a “health test” and what a SNP array actually delivers remains a persistent challenge for the entire DTC genetics industry.

What This Means for Your Health

Genetics is one layer of the longevity equation, but it is not the whole equation. Within Healthcare Discovery‘s longevity framework, inherited genetic variants represent the hand you are dealt, while epigenetic modifications, lifestyle choices, and environmental exposures represent how you play it. The Four Shadows of cardiovascular disease, cancer, neurodegenerative disease, and metabolic dysfunction all have genetic components, but in most cases, lifestyle factors (captured by the Five Pillars of Nutrition, Sleep, Movement, Breathwork, and Mindset) exert equal or greater influence on whether those genetic predispositions manifest as disease.

23andMe’s value is as a screening layer, not a diagnostic one. It can identify specific high-penetrance variants (like BRCA1/2 in Ashkenazi populations) that warrant immediate clinical follow-up. It can flag carrier status for conditions relevant to family planning. It can provide pharmacogenomic insights that may help optimize medication selection. But it cannot tell you your biological age, your current metabolic health, or how well your body is aging. For those questions, you need different tools: epigenetic age testing, blood biomarker panels, wearable devices, and the foundational health practices that the research consistently shows matter most.

The practical recommendation: if you have never had any genetic testing and want a broad, accessible starting point, 23andMe provides a reasonable overview at a reasonable price. If you have a family history of hereditary cancer or cardiac disease, skip DTC testing and go directly to clinical-grade screening through a healthcare provider. And regardless of what your genetics reveal, the evidence is clear that the Five Pillars of foundational health, consistently practiced, remain the most powerful tools available for extending both lifespan and healthspan.

Frequently Asked Questions

Is 23andMe FDA approved?
23andMe has received FDA authorization (not approval; authorization is the correct term for this regulatory pathway) for specific health reports, including BRCA1/2 genetic health risk reports, carrier status reports, and pharmacogenomics reports. This means the FDA has reviewed the analytical validity of the genotyping for those specific variants. The test is not a diagnostic device and is not intended to replace clinical genetic testing ordered by a physician.

How many BRCA variants does 23andMe test for?
23andMe tests for three specific BRCA1/BRCA2 variants that are most common in individuals of Ashkenazi Jewish descent: 185delAG and 5382insC in BRCA1, and 6174delT in BRCA2. There are over 1,000 known pathogenic BRCA variants. A negative result from 23andMe does not rule out BRCA-related cancer risk, particularly for individuals without Ashkenazi Jewish ancestry. Those with family histories of breast or ovarian cancer should pursue clinical-grade BRCA testing.

What is the difference between 23andMe and whole genome sequencing?
23andMe uses a SNP genotyping array that reads approximately 730,000 specific genetic positions. Whole genome sequencing (WGS), offered by companies like Nebula Genomics, reads all 3.2 billion base pairs of the genome. WGS provides orders of magnitude more data, including rare variants, structural changes, and novel mutations that SNP arrays miss. 23andMe is less expensive ($229 vs. $299 to $999 for WGS) and provides more curated health reports, while WGS provides more comprehensive raw genetic data.

Is 23andMe data secure after the data breach?
23andMe experienced a significant data breach in 2023 that exposed genetic and personal data for millions of users. The company has since implemented additional security measures. However, genetic data is uniquely sensitive because, unlike passwords or credit card numbers, it cannot be changed. Users should carefully review 23andMe’s current privacy policies, data sharing settings, and security measures before submitting a sample. Consider downloading and deleting your data from the platform if you have concerns about long-term storage security.

Can 23andMe tell me my biological age?
No. 23andMe tests inherited genetic variants (SNPs), which reflect your fixed genome. Biological age is measured through epigenetic testing, specifically DNA methylation patterns that change over time in response to aging, lifestyle, and environmental factors. Services like TruDiagnostic ($499), Elysium Index ($299), and myDNAge ($299 to $499) measure biological age using epigenetic clocks. These are complementary, not competing, forms of genomic testing.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.